References
- Birnbaum J. E., Cervoni P., Chan P. S., Chen S. M., Floyd M. B., Grudzinskas C. V., Weiss M. J., Dessy F. Prostaglandins and congeners. (16RS)-()-15-deoxy-16-hydroxy-16-vinyl-prostaglandin E2, an orally and transdermally active hypotensive agent of prolonged duration. Journal of Medicinal Chemistry 1982a; 25: 492–494
- Birnbaum J. E., Chan P. S., Cervoni P., Dessy F., Van Humbeeck L. Cutaneous erythema and blood pressure lowering effects of topically applied 16-vinyl prostaglandins. Prostaglandins 1982b; 23(2)185–199
- Chan P. S., Cervoni P., Ronsberg M. A., Accomando R. C., Quirk G. J., Scully P. A., Lipchuck L. M. Antihypertensive activity of dl-15-deoxy-16–1-hydroxy-15-(α/β)-vinyl prostaglandin E2 methyl ester (CL 115,347), a new orally and transdermally long-acting antihypertensive agent. Journal of Pharmacology and Experimental Therapeutics 1983; 226: 726–732
- Cosulich D. B., Perkinson N. A., Batra V. K. Capillary gas chromatographic-mass spectrometric analysis of 15-deoxy-16-hydroxy-16-vinylprostaglandin E2. Journal of Pharmaceutical Sciences 1985; 74(1)76–78
- Nicolau G., Baughman R. A., Tonelli A., McWilliams W., Shiltz J., Yacobi A. Deposition of viprostol (a synthetic PGE2 vasodilator) in the skin following topical administration to laboratory animals. Xenobiotica 1987; 17: 1113–1120
- Nicolau G., Cosulich D. B., Tonelli A., Chen S. M., Pruzinsky M. S., Blum D. Metabolism of viprostol—a synthetic vasodilator PGE2 analog. Prostaglandins 1986; 31(No. 4)811–827
- Yacobi A., Baughman R. A., Cosulich D. B., Nicolau G. Method for determination of first-pass metabolism in human skin. Journal of Pharmaceutical Sciences 1985; 73(10)1499–1500